Enfusion Inc. (ENFN)
NYSE NYSE Primary 
Lost Money on Enfusion, Inc. (ENFN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Investors Invited to Participate in Securities Fraud Investigation Against Enfusion, Inc. with the Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Enfusion, Inc. (ENFN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
Investors Invited to Participate in Enfusion, Inc. Securities Fraud Investigation by the Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE: ENFN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ENFN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on your Enfusion, Inc. Investment
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ATTENTION ENFN SHAREHOLDERS: Investors who lost money on Enfusion, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
Enfusion, Inc. (ENFN) Q2 2024 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - CEO Bradley Herring - CFO Neal Pawar - COO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Gabriela Borges - Goldman Sachs Alexei Gogolev - JPMorgan Matthew Kikkert - Stifel Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Levi & Korsinsky Reminds Shareholders of an Investigation into Enfusion, Inc. (ENFN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Enfusion (ENFN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Enfusion, Inc. (ENFN) Q2 Earnings and Revenues Miss Estimates
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.
